Greg is Treating His Ulcerative Colitis, and Enjoying a Slice or Two | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks to David Gaugh (AAM), Jessica Daley (Premier Inc) and Steven Schondelmeyer (University of Minnesota).
Greg, 37, Los Angeles, CA | Ulcerative Colitis

Greg is Treating His Ulcerative Colitis, and Enjoying a Slice or Two

Greg, 37, of Los Angeles, Cal., spends most of his time hiking, running and lifting weights, but his greatest passion in life is pizza. Not long ago, he made a bet with his wife that he could eat pizza and nothing but pizza for 45 days. As if that weren’t unusual enough, you should know that Greg has a history of ulcerative colitis.

Steroids were not controlling his condition, so his gastroenterologist put him on a biologic medication. After a while, his insurance plan recommended switching to a biosimilar—a safe, effective alternative to a brand-name biologic.

“My doctor was on board,” recalls Greg. “I trust my doctor, so I switched to the biosimilar and it’s been smooth sailing ever since.”


“Given the complexity of drug design,” the Crohn’s and Colitis Foundation informs patients, “Biosimilars cannot be exact copies of biologic therapies, but still contain the same active ingredient, mechanism of action (how they work), and dosing…. Biosimilars are just as safe and effective as the original biologic therapy. There are no clinically meaningful differences.”

How did the bet go? To find out, you’ll have to read The Great Pizza Experiment: How I Ate Nothing but Pizza for Forty-Five Days and Lost Weight, and Other Stories.

Read the 2022 Voices of Access Report

Learn More About Biosimilars

 

Share Your Voice

As we continue to advocate for accessible generics and biosimilars, we will rely more than ever on the voices of real patients. We invite you to share your story on what generic and biosimilar medicines mean to you and urge you to subscribe for advocacy alerts.

Share Your Story

Subscribe for Advocacy Alerts

 

Erica Klinger—Senior Director, Marketing


By Erica Klinger, Senior Director, Marketing
Published on March 23, 2022

 

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.